RENATA KELLY KUNIYOSHI
Projetos de Pesquisa
Unidades Organizacionais
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients(2014) YAMASHITA, Eliana K.; TEIXEIRA, Bianca M.; YOSHIHARA, Renata N.; KUNIYOSHI, Renata K.; ALVES, Beatriz C. A.; GEHRKE, Flavia S.; VILAS-BOAS, Viviane A.; CORREIA, Joao A.; AZZALIS, Ligia A.; JUNQUEIRA, Virginia B. C.; PEREIRA, Edimar Cristiano; FONSECA, Fernando L. A.Background Hyperhomocysteinemia in breast cancer (BC) patients can be a risk factor for thromboembolic events. This study aimed to evaluate homocysteine and its cofators (folic acid and vitamin B12) concentrations and platelet count at diagnosis of BC, 3 and 6 months after the beginning of chemotherapy treatment and to correlate them with clinical data. Methods Thirty-five BC patients were included; blood samples were obtained by venipuncture. Plasmatic Hcy and cofactors concentrations were measured by competitive chemiluminescent enzyme immunoassay method. Platelet count was done using an automated analyzer. Statistical analysis was performed using the software SPSS. Results During chemotherapy, homocysteine (P = 0.032) and vitamin B12 (P < 0.001) concentrations increased, while folate and platelets decreased (P < 0.001). Among the clinical data, the menopausal status showed significant positive correlation (P = 0.022) with homocysteine concentration increase. Conclusions Evaluation of homocysteine concentrations during chemotherapy is extremely important because their levels increase during chemotherapy treatment, thus increasing the risk of thromboembolism development.
- Circulating tumor cell detection during chemotherapy in patients with breast cancer is not associated with plasma homocysteine levels(2013) YOSHIHARA, Renata Nunes; TEIXEIRA, Bianca Marinelli; ADAMI, Fernando; KUNIYOSHI, Renata K.; ALVES, Beatriz C. A.; GEHRKE, Flavia S.; VILAS-BOAS, Viviane A.; AZZALIS, Ligia A.; JUNQUEIRA, Virginia B. C.; PEREIRA, Edimar Cristiano; FONSECA, Fernando L. A.Breast cancer remains the second most frequent type of cancer in the world and the first among women, and systemic chemotherapy is an adjuvant therapeutic modality that improves survival in a great part of patients. Women with breast cancer, however, frequently show a higher risk of thromboembolism, an event associated to hyperhomocysteinemia and the presence of circulating tumor cells (CTC). Our aim is to correlate the presence of CTCs, detected by the analysis of CK19 and c-erbB2 gene expressions, and the homocysteine plasma levels in the peripheral blood in patients with breast cancer undergoing chemotherapy. Epithelial marker expression (CK19 and c-erbB2) and homocysteine levels were analyzed in a mononuclear fraction of the peripheral blood and plasma, respectively, obtained from 35 patients diagnosed with breast cancer at diagnosis and throughout chemotherapy treatment. No significant relation between the CK19 and c-erbB2 expressions and hyperhomocysteinemia was observed at any moment of the evaluation throughout the chemotherapy treatment (3 and 6 months after the onset). Among clinical data, only menopausal status showed a statistically significant correlation with homocysteine concentration. Although differences in the expressions of the analyzed epithelial markers were detected at 3 and 6 months of chemotherapy treatment, no relation between plasma homocysteine variations and the CK19 and c-erbB2 gene expressions was found in patients under chemotherapy treatment at any moment of the evaluation, suggesting that chemotherapy affects the expressions of the studied genes independently.